

AD-A199 085

REPORT DOCUMENTATION PAGE

SELECTED
SEP 08 1988

2b DECLASSIFICATION / DOWNGRADING SCHEDULE NA		1b RESTRICTIVE MARKINGS NA	
4 PERFORMING ORGANIZATION REPORT NUMBER(S) NA		3 DISTRIBUTION / AVAILABILITY OF REPORT Unlimited	
6a NAME OF PERFORMING ORGANIZATION University of California Los Angeles	6b OFFICE SYMBOL (if applicable) NA	7a NAME OF MONITORING ORGANIZATION Office of Naval Research	
6c ADDRESS (City, State, and ZIP Code) Dept. of Medicine, 37-055 CHS UCLA School of Medicine Los Angeles, CA 90024		7b ADDRESS (City, State, and ZIP Code) 800 N. Quincy St. Arlington, VA 22217-5000	
8a NAME OF FUNDING / SPONSORING ORGANIZATION Office of Naval Research	8b OFFICE SYMBOL (if applicable) ONR	9 PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER N00014-86-K-0525	
8c ADDRESS (City, State, and ZIP Code) 800 N. Quincy St. Arlington, VA 22217-5000		10 SOURCE OF FUNDING NUMBERS	
		PROGRAM ELEMENT NO 61153N	PROJECT NO RRO4106
		TASK NO.	WORK UNIT ACCESSION NO.
11 TITLE (Include Security Classification) (U) STRUCTURE AND DESIGN OF MULTIPOTENT PEPTIDE MICROBICIDES			
12 PERSONAL AUTHOR(S) Michael E. Selsted, Ph.D., M.D.			
13a. TYPE OF REPORT annual	13b. TIME COVERED FROM 8/1/87 TO 8/1/88	14 DATE OF REPORT (Year, Month, Day) 8/1/88	15. PAGE COUNT
16. SUPPLEMENTARY NOTATION			
17 COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	
		Peptides, microbicides, structure-function, synthetic peptides	
19. ABSTRACT (Continue on reverse if necessary and identify by block number)			
<p>A family of antimicrobial leukocyte peptides has been isolated from the neutrophils of several species. I am using the consensus structure of the peptides (known as defensins) as a molecular foundation for generating new antimicrobial peptides by synthetic methods. The synthetic approach is directed by correlating the solution structures of various defensins with their distinctive biological activities.</p>			
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION (U)	
22a NAME OF RESPONSIBLE INDIVIDUAL Dr. Michael Marron		22b TELEPHONE (include Area Code) (202) 696-4986	22c OFFICE SYMBOL ONR

DD FORM 1473, 84 MAR

83 APR edition may be used until exhausted.

SECURITY CLASSIFICATION OF THIS PAGE

DISTRIBUTION STATEMENT A

All other editions are obsolete.

Approved for public release;
Distribution Unlimited

Structure and Design of Multipotent Peptide Microbicides

ONR-N00014-86-K-0525
 Michael E. Selsted
 UCLA Department of Medicine
 Center for the Health Sciences
 Los Angeles, CA 90024

ANNUAL REPORT

Project goal. The goal of this project is to design novel peptide antibiotics using a naturally occurring family of peptides, known as defensins, as models. Defensins are homologous peptides, 29-34 residues in length, which are major constituents of the cytoplasmic granules of polymorphonuclear leukocytes. The structural hallmark of the defensin peptide family is a conserved infrastructure comprised of 1 arginine, 1 glycine, and 6 disulfide-linked cysteine residues (Fig. 1). Although the peptides are similar in their overall fold, they possess diverse antimicrobial spectra and potencies. By correlating specific biocidal activities with unique structural features, we seek to design custom peptide antimicrobials based on structure-function principles derived from these studies. Insight into the molecular details of the peptide-target cell interactions may contribute to the general understanding of protein-membrane recognition processes.

		1	10	20	30																														
HUMAN	HNP-1	A	C	Y	C	R	I	P	A	C	I	A	G	E	R	R	Y	G	T	C	I	Y	Q	G	R	L	W	A	F	C	C				
	HNP-2	C	Y	C	R	I	P	A	C	I	A	G	E	R	R	Y	G	T	C	I	Y	Q	G	R	L	W	A	F	C	C					
	HNP-3	D	C	Y	C	R	I	P	A	C	I	A	G	E	R	R	Y	G	T	C	I	Y	Q	G	R	L	W	A	F	C	C				
GUINEA PIG	GPNP	R	R	C	I	C	T	T	R	T	C	R	F	P	Y	R	R	L	G	T	C	I	F	Q	N	R	V	Y	T	F	C	C			
RABBIT	NP-1	V	V	C	A	C	R	R	A	L	C	L	P	R	E	R	R	A	G	F	C	R	I	R	G	R	I	H	P	L	C	C	R	R	
	NP-2	V	V	C	A	C	R	R	A	L	C	L	P	L	E	R	R	A	G	F	C	R	I	R	G	R	I	H	P	L	C	C	R	R	
	NP-3A	G	I	C	A	C	R	R	R	F	C	P	N	S	E	R	F	S	G	Y	C	R	V	N	G	A	R	Y	V	R	C	C	S	R	R
	NP-3B	G	R	C	V	C	R	K	Q	L	C	S	Y	R	E	R	R	I	G	D	C	K	I	R	G	V	R	F	P	F	C	C	P	R	
	NP-4	V	S	C	T	C	R	R	F	S	C	G	F	G	E	R	A	S	G	S	C	T	V	N	G	V	R	H	T	L	C	C	R	R	
NP-5	V	F	C	T	C	R	G	F	L	C	G	S	G	E	R	A	S	G	S	C	T	I	N	G	V	R	H	T	L	C	C	R	R		

Figure 1. Covalent structures of defensins. The single letter amino acid code for ten defensin peptides from the indicated sources are shown maximally aligned. Invariant residues are outlined. The cysteine connectivities are also indicated.

Recent Progress:

1. Isolation of new members of the defensin family. Using methods established for the identification, purification, and characterization of rabbit, human, and guinea pig defensins, we isolated three new members of this peptide family from rat peritoneal neutrophils. The new members of the defensin family retain the conserved (6 Cys, 1 Gly, 1 Arg) infrastructure, are 29-32 residues in length, and have similar broad spectrum antimicrobial activities as many of the previously characterized defensins. Comparison of their structures and biocidal activities will be used for correlating residue-specific antimicrobial function(s).

2. Chemical modifications of defensins. By comparing the antimicrobial spectra of various members of the defensin family, we found that HNP-1 and HNP-3 have distinctly different potency against fungal test organisms (*Candida albicans*) even though these two defensins vary in sequence by a single residue (Fig. 1). This suggested that the amino terminal portion of the peptide plays an important role in function. To probe the relationships between the structure and function at this molecular locus, we have evaluated the effects of various covalent modifications of the amino terminus of HNP-1. We have developed methods for specific modification, purification, and characterization of Ala₁ derivatives of HNP-1 using fluorescein isothiocyanate, succinic anhydride, ethylacetimidate, and cyanate. While the characterization of the activities of these HNP-1 derivatives is not yet complete, our preliminary studies indicate that fluorescenation (conversion to a neutral amino terminus) abolishes HNP-1 activity, and amidination (with retention of native amino terminal charge) results in a compound with activity equal to that of the unmodified peptide. We are likewise generating defensin derivatives modified at the C-terminus using carbodiimide-mediated coupling of taurine, glycinamide, and arginine amide.

3. Solution Structures. In collaborative studies performed with Arthur Pardi, we have determined the solution structures of four defensin peptides: human defensins HNP-1 and

Original contains color plates: All BMS reproductions will be in black and white

TIC
D
COPY
INSPECTED
SP1

or

Special

A-1

HNP-3, and rabbit defensins NP-2 and NP-5. The solution structures were determined by 2-D NMR experiments (see list of publications) and refined by superimposing the disulfide array which we determined by a novel method. As anticipated, the four defensins studied by this technique have very similar structures. A space filling model of HNP-1 is shown in Figure 2, demonstrating that this defensin possesses an amphiphilic topology.




Figure 2 Space filling model of HNP-1 derived from NMR spectroscopy and covalent structure determination. Main chain atoms are shown in white, charged residues are shown in red, weakly polar residues are shown in blue, and hydrophobic residues are green or yellow (cystines).

One face of the peptide is comprised of hydrophobic residues, while the charged R groups are segregated, and are substantially clustered. The folded configuration is unique among peptides of known structure, and it varies in particular from amphiphilic alpha helical structures which have been described. The significance of the amphiphilic array is discussed below.

4. Membrane active features of defensins. A number of experimental observations regarding the range of defensin bioactivities suggested that they act at the level of the target membrane: the peptides are active against prokaryotes, eukaryotes, and enveloped (but not naked) viruses; susceptible targets are protected by temperatures below the phase-transition point of the target membranes; bacteria and fungi are rendered insensitive to defensins by proton ionophores such as DNP or CCCP. We have now shown that at least two defensins, HNP-1 and NP-1, form voltage-dependent channels in lipid bilayer membranes. The pores formed 1) require specific orientation of the voltage potential, 2) are anion selective, 3) are heterogeneous, and 4) appear to require the association of 2-4 monomers in the bilayer. These features are consistent with a novel oligomeric membrane channel which likely contributes to the biocidal mechanisms of defensin peptides.

5. Synthetic Defensins. We previously reported the synthesis of the rabbit defensin NP-2 using t-BOC chemistry and HF cleavage. The yield by this method was approximately 5%. We have modified the protocol used for synthesis and refolding such that our yields are now ca. 22%. This was accomplished by using TFMSA cleavage and modified conditions for peptide refolding and disulfide oxidation. With the knowledge gained from development of NP-2 synthesis conditions, we have succeeded in synthesizing more than 200 mg of the human defensin HNP-1. This peptide contains 30 residues, which include 3 tyrosines, 1 tryptophan, and 6 cysteines. A manuscript describing the conditions used for synthesis, cleavage, deprotection, refolding, and biologic activities of synthetic HNP-1 is in preparation. The ability to synthesize the quantities of this and related defensins will allow us to perform material-consuming studies which would otherwise be impossible. Further, we are now well positioned for the synthesis of defensin congeners, a major goal of this project.

6. Crystallographic studies. Ongoing analysis of diffraction quality crystals of the rabbit defensin NP-2 and the human defensin HNP-1 have proceeded to the point of tracing the

main chain of both peptides. While both NP-2 and HNP-1 form high quality crystals, we have had difficulty in generating heavy atom derivatives for isomorphous replacement studies. In order to increase the number of possible crystal forms amenable to heavy atom derivatives, we sought to crystallize the human defensin HNP-3. With its amino terminal aspartate, we surmised that a heavy cation might bind to this site. High grade crystals HNP-3 were recently grown at pH 4.05 from a precipitant of sodium citrate, ethanol and polyethylene glycol (Fig. 3). We are currently characterizing the crystal space group, and will collect native data sets shortly.




Figure 3 10X photo of crystals of HNP-3

- AZEL, Marco
Department of Biophysics
Johns Hopkins School of Medicine
725 North Wolfe Street
Baltimore, MD 21205
- ANDERSON, Niels H.
Department of Chemistry
University of Washington
Seattle, WA 98195
- AGUST, J. Thomas
Department of Pharmacology
Johns Hopkins Medical School
725 North Wolfe Street
Baltimore, MD 21205
- BENDER, Myron L.
Chemistry Department
Northwestern University
Evanston, IL 60201
- BEVERIDGE, David L.
Department of Chemistry
Wesleyan University
Hall-Altwater Laboratories
Middletown, CT 06457
- BILTONEN, Rooney L.
Department of Pharmacology
University of Virginia
Charlottesville, VA 22908
- BRANSON, H. Neal
Department of Biochemistry, Box 607
University of Rochester Medical Center
531 Elmwood Avenue
Rochester, NY 14642
- CHANG, Eddie L.
Bio/Molecular Engineering
Code 6190
Naval Research Laboratory
Washington, D.C. 20375-5000
- ERICKSON, Bruce
Chemistry Department
University of North Carolina
Chapel Hill, NC 27514
- FEIGON, Juli F.
Department of Chemistry & Biochemistry
University of California
405 Hilgard Avenue
Los Angeles, CA 90024-1569
- FICHT, Allison R.
Dept of Medical Biochem & Genetics
Texas A&M University
College Station, TX 77843
- FORTES, P. A. George
Department of Biology
University of California-San Diego
La Jolla, CA 92093
- FRANKEL, Richard B.
Massachusetts Institute of Technology
Francis Bitter National Laboratory
Cambridge, MA 02139
- FRAUENFELDER, Hans
Department of Physics
University of Illinois
Urbana, IL 61801
- GABER, Bruce P.
Code 6190 Bio/Molecular Engineering
Naval Research Laboratory
Washington, DC 20375
- GOODMAN, Eugene M.
Biomedical Research Institute
University of Wisconsin
Kenosha, WI 53141
- HO, Pui Shing
Department of Biochem and Biophysics
Oregon State University
Corvallis, OR 97331
- HOFFMAN, Brian M.
Department of Chemistry
Northwestern University
Evanston, IL 60201
- HONIG, Barry
Columbia University
Dept of Biochem and Molec Biophysics
530 West 168th St.
New York, NY 10032
- HOPKINS, Paul B.
Department of Chemistry
University of Washington
Seattle, WA 98195
- KIRCHMAN, David L.
College of Marine Studies
University of Delaware
Robinson Hall
Newark, DE 19716
- LAURSEN, Richard
Chemistry Department
Boston University
590 Commonwealth Avenue
Boston, MA 02215
- LESZ, Robert W.
Chemical Engineering Department
University of Massachusetts
Amherst, MA 01003
- LEWIS, Randolph V.
Biochemistry Department
University of Wyoming
University Station Box 3944
Laramie, WY 82071
- LINDSAY, Stuart M.
Department of Physics
Arizona State University
Temp, AZ 85278
- LOEB, George J.
David W. Taylor Research Center
Code 2841
Annapolis, MD 21402-5067
- MCCONNELL, Harden M.
Stanford University
Department of Chemistry
Stanford, CA 94305
- MERTES, Kristin Bowman
University of Kansas
Dept of Chemistry
Lawrence, Kansas 66045
- NAGUMO, Mark
Bio/Molecular Engineering, Code 6190
Naval Research Laboratory
Washington, DC 20375-5000
- NOVOTNY, Jiri
Lab for Cellular and Molecular Test
Massachusetts General Hospital
Boston, MA 02114
- PABC, Carl C.
Department of Biophysics
Johns Hopkins University
School of Medicine
Baltimore, MD 21205
- PRENDERGAST, Franklyn
Mayo Foundation
200 First St. SW
Rochester, MN 55905
- PRIMOR, Naitali
New York Zoological Society
New York Aquarium
Osborne Lab of Marine Science
Brooklyn, NY 11224
- RACKOVSKY, Shalom R.
Department of Biophysics
University of Rochester
School of Medicine and Dentistry
Rochester, NY 14642
- RAJAN, K. S.
Illinois Institute of Technology
Research Institute
10 W. 35th St.
Chicago, IL 60616
- REINISCH, Lou
Department of Physics
Northeastern University
360 Huntington Avenue
Boston, MA 02115
- RICH, Alexander
Department of Biology
Massachusetts Institute of Technology
Cambridge, MA 02139
- RICHARDS, J. H.
California Institute of Technology
Div of Chemistry and Chem Engineer.
Pasadena, CA 91125
- ROTHSCHILD, Kenneth J.
Department of Physics
Boston University
590 Commonwealth Avenue
Boston, MA 02215
- SCHULTZ, Peter G.
University of California
Dept of Chemistry
Berkeley, CA 94720
- SELSTED, Michael E.
Univ of CA Los Angeles
Dept of Medicine
37-055 CHS
Los Angeles, CA 90024
- SIGMAN, David S.
JCLA School of Medicine
Dept of Biological Chemistry
Los Angeles, CA 90024
- STEEB, Steven J.
Department of Biophysics Sciences
University of South Alabama
Mobile, AL 36688
- SINSKEY, Anthony J.
Laboratory of Applied Microbiology
Department of Applied Biophysics
Sciences
Massachusetts Institute of Techno
Cambridge, MA 02139
- STEWART, James M.
Department of Chemistry
University of Maryland
College Park, MD 20742
- TAYLOR, Gordon T.
Hawaii Institute of Geosciences
University of Hawaii
2525 Conna Road
Honolulu, HI 96822
- TOSTFOSW, Thomas R.
Department of Marine Sciences
University of Puerto Rico
Mayaguez, PR 00886
- URRY, Jan W.
Laboratory of Molecular Biophysics
University of Alabama
P. O. Box 311
Birmingham, AL 35204
- WAITE, J. Herbert
College of Marine Studies
University of Delaware
Lewes, DE 19959
- WARD, Keith B.
Naval Research Laboratory
Laboratory for Molecular Biology
Code 6030
Washington, DC 20375
- WARSHEL, Arlen
Department of Chemistry
University of Southern California
University Park
Los Angeles, CA 90089-0482
- WHITE, David C.
Department of Microbiology
Institute of Applied Microbiology
University of Tennessee
Knoxville, TN 37996-0345
- WILLIAMS, Jan J.
Allied Corporation
Columbia Rd and Park Ave.
Morristown, NJ 07960

END

DATE

FILMED

DTIC

10-88